<DOC>
	<DOCNO>NCT01392521</DOCNO>
	<brief_summary>The PI3K ( phosphoinositol 3-Kinase ) inhibitor Copanlisib MEK ( mitogen-activated protein kinase ) inhibitor Refametinib ( BAY86-9766 ) test single agent treatment phase I study . This study test combination two drug try answer follow question : 1 . What side effect combination Copanlisib Refametinib ( BAY86-9766 ) give together different/increasing dose level ? 2 . What dose level Copanlisib Refametinib ( BAY86-9766 ) test future clinical research study ? 3 . How much Copanlisib blood specific time administration add Refametinib ( BAY86-9766 ) affect ? 4 . How much Refametinib ( BAY86-9766 ) blood specific time administration add Copanlisib affect ? 5 . Does combination Refametinib ( BAY86-9766 ) Copanlisib effect tumor ?</brief_summary>
	<brief_title>Phase Ib Study PI3 ( Phosphoinositol 3 ) -Kinase Inhibitor Copanlisib With MEK ( Mitogen-activated Protein Kinase ) Inhibitor Refametinib ( BAY86-9766 ) Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Age great than/equal 18 year old ECOG Performance Status 0 1 Life expectancy least 12 week Patients advance , histologically cytologically confirm solid tumor , refractory standard therapy standard therapy available LVEF ( leave ventricular ejection fraction ) &gt; = low limit normal institution Radiographically clinically evaluable tumor Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 14 day prior start first dose : Hemoglobin &gt; 9.0 g/dL Absolute neutrophil count ( ANC ) &gt; = 1500/mm3 Platelet count &gt; = 100,000 /mm3 Total bilirubin &lt; = 1.5 time upper limit normal ALT ( alanine aminotransferase ) AST ( aspartate aminotransferase ) &lt; = 2.5 x upper limit normal ( &lt; = 5 x upper limit normal patient liver involvement ) PTINR ( prothrombininternational normalize ratio ) PTT ( partial thromboplastin time ) &lt; = 1.5 time upper limit normal Serum creatinine &lt; = 1.5 time upper limit normal History impair cardiac function clinically significant cardiac disease ( i.e . congestive heart failure ( CHF ) NYHA ( New York Heart Association ) Class III IV ) ; active coronary artery disease , myocardial infarction within 6 month study entry ; new onset unstable angina within 3 month study entry , cardiac arrhythmia require antiarrhythmic therapy Type 1 type 2 diabetes mellitus fast glucose &gt; 125 mg/dL HgBA1c &gt; = 7.0 Use systemic corticosteroid within 2 week study entry History retinal vein occlusion Known glucose6phosphate dehydrogenase ( G6PD ) deficiency Active clinically serious infection Uncontrolled hypertension Positive HIV , chronic Hepatitis B C Subjects undergoing renal dialysis Known bleeding diathesis Ongoing substance abuse Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>